Alpha-1 Antitrypsin Deficiency (AATD)

more news >>

Latest Clinical Trials


more insights >>

Patient Perspectives

more columns >>

Alpha-1 Features

more features >>

Rare Care Podcast

Israeli biopharma giant Kamada is banking that its inhaled AAT therapy will “revolutionize” the treatment of alpha-1 antitrypsin deficiency (AATD).

Mark Brantly, MD, scientific director of the Alpha-1 Foundation, is the vice-chair of research in the Department of Medicine at the University of Florida in Gainesville, and has spent most of his career researching a cure for alpha-1 antitrypsin deficiency (AATD).

Alpha-1 Meeting Coverage